Congenital nonobstructive nonhaemolytic hyperbilirubinaemia (Crigler-Najjar disease) is characterized by the presence ofhigh levels ofunconjugated bilirubin in the blood resulting from a congenital deficiency of glucuronyl transferase activity. To date some 86 cases have been published but this is an exaggerated figure as there has been some duplication of reporting. A full bibliography has been compiled by the authors and is available on request.
Arias et al. (1969) described two varieties of the disease, type I and type II. Those patients with type I are deeply jaundiced with serum unconjugated bilirubin levels of 17 to 40 mg/100 ml; they do not respond to treatment with phenobarbitone; they have no bilirubin glucuronide in their bile; inheritance appears to be in an autosomal recessive manner, and almost all have developed kernicterus. Those patients with type II have lower levels of bilirubin ranging from 4 to 20 mg/100 ml; they respond dramatically to treatment with phenobarbitone; they have normal levels of bilirubin glucuronide in their bile; inheritance is probably in an autosomal dominant manner, and most survive without neurological damage. Both types have very low levels of glucuronyl transferase activity in liver biopsy samples, with no significant difference between the two types. The cases originally described by Crigler and Najjar (1952) were probably all of Arias type I. Treatment of Arias type I disease became possible with the advent of phototherapy and has prevented or delayed the development of kernicterus in many of the patients on which it has been used (Altay and Say, 1973; Bethenod et al., 1967; Callahan et al., 1970; Gorodischer et al., 1970; Gotze et al., 1972; Karon, Imach, and Schwartz, 1970; Land, Zarkowsky, and Vietti, 1970; Nicola and Mussa, 1967; Salazar De Sousa, 1964) .
In our patient phototherapy has succeeded in keeping serum bilirubin levels within safe limits, but it has also necessitated her remaining in hospital as she usually requires 20 hours of phototherapy each day. We are very much aware that her normal development may be impeded by this 
Subsequent progress
The patient is now aged 2 years. She has remained jaundiced with bilirubin levels ranging from 10 to 28 mg/100 ml, being usually between 14 and 19 mg/100 ml. Despite prolonged hospitalization her mental and physical development have been well within normal limits.
Treatment trials
Our patient was given, in turn, aspartic acid, a high fat diet, phenobarbitone, uridine di-phosphoglucose, cholestyramine, and agar. Each of these treatments was given for a period of 3 weeks with intervals of at least 3 weeks between treatments. All other variables (e.g. amount of phototherapy, diet) were kept as constant as possible. Serum bilirubin concentrations were determined (by modification of the method of Powell, 1944) in duplicate, on venous blood, three times a week, care being taken to protect the blood samples from light during transit to the laboratory.
Aspartic acid. Both aspartic acid and orotic acid have been used for treating unconjugated hyperbilirubinaemia, and both substances have been shown to be effective in reducing neonatal jaundice (Kintzel, Hinkel, and Schwarze, 1971; Matsuda and Shirahata, 1966) though this has been disputed by Gray and Mowat (1971) and Mowat (1971) . Aspartic acid is probably more effective than orotic acid (Matsuda and Shirahata, 1966) , and as orotic acid has been associated with mortality in rats, it was not used on our patient. These substances have been used because they are precursors of uridine di-phosphoglucuronic acid which is a substrate in bilirubin conjugation. We used potassium L-aspartate in a dose of 300 mg twice daily.
High fat diet. Housset et al. (1967) and Barrett (1971) have shown that a high fat diet reduces serum bilirubin levels in Gunn rats (rats having the equivalent of human Crigler-Najjar disease, Arias type I). The rationale is that fat-soluble unconjugated bilirubin which passes into the intestinal lumen other than in the bile (Lester, Hammaker, and Schmid, 1962) , is held there if the intestinal contents are high in fat concentration. We increased the fat content of our patient's diet to an average of 66-9 g/day compared with 35 g/day before and after the treatment period.
Phenobarbitone. There is now much evidence that phenobarbitone is capable of inducing the enzyme glucuronyl transferase in normal persons. In patients with Arias type II Crigler-Najjar disease, phenobarbitone has been effective in reducing levels of unconjugated bilirubin (Arias et al., 1969; Arias, 1971; Crigler and Gold, 1969; Gotze et al., 1972, Kreek and Sleisenger, 1968; Newton and Ertel, 1968) . Phenobarbitone has had no effect, however, on the bilirubin levels of patients with Arias type I disease (Arias et al., 1969; Gotze et al., 1972) ; indeed the response to phenobarbitone appears to be an effective method of determining whether the patient has Arias type I or type II disease.
Phenobarbitone 15 mg daily was given to our patient in the neonatal period without obvious effect before we realized she had Crigler-Najjar disease. Subsequently two further treatment periods confirmed that the drug had no effect.
Uridine di-phosphoglucose (UDPG). UDPG has been used for the treatment of neonatal jaundice and has been shown to be effective in reducing bilirubin levels (Careddu and Marini, 1968; Marini, 1969) . Unfortunately, UDPG is expensive and has to be given intramuscularly. We used UDPG 20 mg twice daily and found no significant effect.
Cholestyramine. Cholestyramine has been successfully used to treat jaundice due to biliary atresia (Lottsfeldt et al., 1963) , to cirrhosis in adults (Visintine et al., 1961) , and in Gunn rats (Lester et al., 1962) . Girotti et al. (1969) , however, found no effect in a 5-day trial in one patient with presumed Crigler-Najjar disease; and both Nicola and Mussa (1967) and Blumenschein et al. (1968) found no effect in their patients with Crigler-Najjar disease, though dose and duration of treatment are not stated in the former. One of the patients described by Kreek and Sleisenger (1968) may have benefited from cholestyramine, though very little detail is given.
The rationale of its use is that, like fat, it holds bilirubin in the intestinal lumen (but by adsorption) and interrupts the enterohepatic circulation. We used cholestyramine in a dose of 2 g twice daily.
Agar (Table) . Agar, whenfed to Gunn rats in laxative doses, has been shown to increase faecal bilirubin excretion, to improve growth rate, to lower mortality, and to protect partially against bilirubin nephropathy; and when given to neonates from age 20 hours for 4 days, bilirubin levels were lowered significantly (Poland and Odell, 1971 ). In addition, agar has been shown to reduce bilirubin levels in a patient with
Crigler-Najjar disease (Poland, 1973) .
The rationale for using agar is that it can interrupt the enterohepatic circulation of bilirubin by 'stabilizing it and preventing its bacterial conversion'.
Agar was given to our patient for 6 days at age 42 days without obvious effect. A further trial was undertaken at the age of 21 months. A number of preparations were examined for percentage inhibition of bacterial degradation by the patient's own bowel flora, using the method of Poland and Odell, (1971 group.bmj.com on July 7, 2017 -Published by http://adc.bmj.com/ Downloaded from variation of this magnitude was seen during the control period, and, in spite of the statistical significance of the regression, interpretation is difficult. It is interesting that during treatment with a high fat diet there appeared to be an absolute fall of about 4 mg/100 ml without any gradual progressive change, and analysis by linear regression is probably inappropriate. The most striking evidence of an effect of treatment is seen during the cholestyramine treatment period when there was a highly significant and convincing fall of serum bilirubin concentration with time (P1 <0 001) of about 6-5 mg/100 ml, and a highly significant rise again in the following control period (P1 <0 001).
Discussion
We found cholestyramine to be the most successful and most easily applied supplement to phototherapy. It has enabled us to reduce the amount of phototherapy given to our patient, allowing her greater freedom. Her bilirubin values over some 4 months of continuous treatment with cholestyramine are significantly lower (mean 12-3, SD 2 0) than in the 8-week control period (mean 15-5, SD 1-6; P <0 001) despite this greater freedom and reduction in phototherapy time. A recent attempt to repeat the treatment trial with cholestyramine was abandoned because the bilirubin level rose to over 20 mg/100 ml within 10 days of stopping the drug.
In view of the known possible complications of long-term cholestyramine therapy, she has vitamin supplements and her alkaline phosphatase levels and prothrombin time are checked periodically. She has started going home during the daytime (at present only 2 days each week) to return in the evening to hospital to sleep under the phototherapy unit. Her present bilirubin levels range from 9 0 to 14 0 mg/100 ml despite her days at home. We look forward to her being able to stay at home every day, probably sleeping each night at the hospital for phototherapy and occasional checks on bilirubin levels. 
